Saisheng Pharmaceutical: Subsidiary Withdraws Drug Registration Application for Dapagliflozin Tablets

MetaMuskRat · 2026-03-22T02:10:55+00:00

Saizheng Pharmaceutical announced that its subsidiary Beijing Saiersheng Biotechnology has withdrawn the drug registration application for Dapagliflozin Tablets due to the need to further improve the documentation. The application was submitted and accepted in 2025. The company will make timely information disclosures.

MetaMuskRat

2026-03-22 02:10:55

Abstract generation in progress

People’s Financial News, March 20 — Sai Sheng Pharmaceutical (300485) announced on March 20 that its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., recently received a “Notice of Termination of Drug Registration Application” issued by the National Medical Products Administration. The notice approves Sai Er Biological’s withdrawal of the registration application for Dapagliflozin tablets. Sai Er Biological submitted an application for marketing approval of Dapagliflozin tablets to the NMPA in March 2025 and it was accepted. Due to changes in policies and regulations, the company needs to further improve the submission materials. After careful consideration, the company has decided to voluntarily withdraw this application. The company will fulfill its information disclosure obligations in a timely manner based on the project situation.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes